Patients with FTD, including those with CHMP2B mutations, display changes in personality and behaviour as well as motor dysfunction (6,29); therefore behavioural testing was used to assess disease-relevant deficits in the CHMP2BIntron5 mouse model at 6, 12 and 18 months of age compared with both non-transgenic and CHMP2BWildtype controls. The gene discussed is CHMP2B; the disease is frontotemporal dementia.